Item 8.01 Other Information.

On June 17, 2020, Cara Therapeutics, Inc. issued a press release announcing the completion of the interim statistical assessment for its KARE Phase 2 clinical trial of Oral KORSUVA in atopic dermatitis patients with moderate-to-severe pruritus. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

© Edgar Online, source Glimpses